---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-088728"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2026-07-30T20:30:36+00:00"
generated_at: "2026-07-30T20:32:17.860914+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BrainStorm appoints former FDA official Peter Pitts as Executive Chairman; Frenkel and Dagher depart

## Summary
- Peter Pitts, former FDA Associate Commissioner, appointed Executive Chairman and Chief Strategic Regulatory Officer on July 24, 2026.
- Jacob Frenkel resigned as Chairman and director; transitions to Senior Advisor with 100,000 RSUs vesting over 6 months.
- Ibrahim Dagher resigned as EVP and Chief Medical Officer on July 26, 2026; will consult for one year with equity vesting.
- Pitts will lead NurOwn Phase 3b trial under first-ever FDA Special Protocol Assessment for an ALS therapeutic.
- Pitts receives option for 900,000 shares vesting over 4 years; no salary or cash bonus.

## SEC filing metadata
- accession: 0001104659-26-088728
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2026-07-30T20:30:36+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465926088728/0001104659-26-088728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465926088728/tm2621592d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-088728
- JSON: https://secwatch.observer/filing/0001104659-26-088728.json
- Plain text: https://secwatch.observer/filing/0001104659-26-088728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.